Evidence map›Paper›PMID 36752960›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2023

Correction to: New update to the guidelines on testing predictive biomarkers in non‑small‑cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Dolores Isla, Maria D Lozano, Luis Paz-Ares, Clara Salas, Javier de Castro, Esther Conde, Enriqueta Felip, Javier Gómez-Román, Pilar Garrido, Ana Belén Enguita

Abstract readPublished Erratum
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Dolores IslaLozano Blesa University Clinical Hospital, IIS Aragón, Spanish Society of Medical Oncology (SEOM), C. de San Juan Bosco, 15, 50009, Zaragoza, Spain. lola.isla@gmail.com.ORCID http://orcid.org/0000-0002-2483-198X
Maria D LozanoClínica Universidad de Navarra, Spanish Society of Cytology (SEC), Spanish Society of Pathology (SEAP), Pamplona, Spain.
Luis Paz-Ares12 de Octubre University Hospital, Spanish Society of Medical Oncology (SEOM), Madrid, Spain.
Clara SalasPuerta de Hierro University Hospital, Spanish Society of Pathology (SEAP), Madrid, Spain.
Javier de CastroLa Paz University Hospital, Hospital La Paz Institute for Health Research (IdiPAZ), Spanish Society of Medical Oncology (SEOM), Madrid, Spain.
Esther Conde12 de Octubre University Hospital, Research Institute 12 de Octubre University Hospital (I+12), Spanish Society of Pathology (SEAP), Madrid, Spain.
Enriqueta FelipVall d'Hebron University Hospital, Spanish Society of Medical Oncology (SEOM), Barcelona, Spain.
Javier Gómez-RománCantabria University, Marqués de Valdecilla University Hospital, Valdecilla Biomedical Research Institute (IDIVAL), Spanish Society of Pathology (SEAP), Santander, Spain.
Pilar GarridoRamón y Cajal University Hospital, Spanish Society of Medical Oncology (SEOM), Madrid, Spain.
Ana Belén Enguita12 de Octubre University Hospital, Spanish Society of Pathology (SEAP), Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID36752960
PMCPMC10119196

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.